Our team has experience and in-depth knowledge of how to isolate nucleic acids from tumor areas of FFPE sections delineated by our pathologists
Employing both standard (the BioMark™ HD) and cutting-edge (nCounter®) platforms from Fluidigm and NanoString® respectively, we offer solutions for the high-throughput gene expression needs of our clients. The high-throughput capabilities of the nCounter® and the BioMark™ HD systems allow for rapid expression analysis of hundreds of genes from thousands of samples.
The complementary technologies of Nanostring’s digital quantification of nucleic acids based on color-coded barcodes and Fluidigm’s nanolitre volume RT-PCR reactions driven by a microfluidics platform can also be used for gene fusion analysis, SNP genotyping, and copy number variation. In addition, we provide services for developing and validating gene expression assays for low-throughput studies on our ABI real-time PCR systems.
Our team has experience and in-depth knowledge of how to isolate nucleic acids from tumor areas of FFPE sections delineated by our pathologists. The combination of our expertise with the above technologies allows us to readily analyze large numbers of clinical trial samples for our clients.